专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10494647B2 HIV pre-immunization and immunotherapy 有权
公开(公告)号：US10494647B2
公开(公告)日：2019-12-03
申请号：US16218010
申请日：2018-12-12
申请人： American Gene Technologies International Inc.
发明人： Charles David Pauza , Haishan Li , Tyler Lahusen , Jeff Galvin
IPC分类号： A61K48/00 , C12N15/85 , A61K9/127 , C07K14/47 , C12N15/11 , C12N15/86 , C12N15/113 , C12N5/078 , A61K35/14 , A61K39/39 , C12N7/00 , A61P31/18 , A61K39/00 , A61K35/12 , A61K39/12 , A61K35/15
CPC分类号： C12N15/86 , A61K35/14 , A61K39/39 , A61P31/18 , C12N5/0634 , C12N7/00 , C12N15/1132 , C12N15/1138 , A61K35/15 , A61K39/12 , A61K2035/124 , A61K2039/55561 , C12N2310/141 , C12N2320/32 , C12N2330/51 , C12N2510/00 , C12N2740/15021 , C12N2740/15034 , C12N2740/15043 , C12N2740/15052
摘要： The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

2. 发明申请

US20170107285A1 BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND ENCODING POLYNUCLEOTIDES THEREOF 审中-公开
公开(公告)号：US20170107285A1
公开(公告)日：2017-04-20
申请号：US15233140
申请日：2016-08-10
申请人： Seattle Children's Hospital d/b/a Seattle Children's Research Institute
发明人： Michael Jensen
IPC分类号： C07K16/28 , C07K14/725 , A61K35/17 , C07K14/71 , C12N7/00 , C07K14/705 , C12N5/0783
CPC分类号： C07K16/2803 , A61K35/17 , A61K38/00 , A61K38/179 , A61K47/6849 , A61K2039/505 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K16/2887 , C07K16/2896 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N7/00 , C12N2510/00 , C12N2740/15021 , C12N2740/15043 , Y02A50/473
摘要： The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

3. 发明授权

US6107077A Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines 失效
标题翻译：能够产生FIV的FIV诊断和疫苗的猫淋巴细胞系
公开(公告)号：US6107077A
公开(公告)日：2000-08-22
申请号：US995304
申请日：1992-12-21
申请人： Janet K. Yamamoto
发明人： Janet K. Yamamoto
IPC分类号： A61K39/00 , A61K39/21 , C07K14/155 , C12N7/00 , C12N5/06
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , C12N7/00 , A61K2039/5252 , A61K2039/545 , A61K2039/552 , A61K2039/5555 , A61K2039/55566 , A61K2039/575 , A61K39/00 , C12N2740/15021 , C12N2740/15022 , C12N2740/15034 , C12N2740/15051
摘要： Compositions derived from a novel viral isolate designated feline immunodeficiency virus (FIV) include the whole virus, proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FIV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses inactivated cell lines expressing FIV antigens, and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).
摘要翻译：衍生自指定为猫免疫缺陷病毒（FIV）的新型病毒分离物的组合物包括来源于病毒的全部病毒，蛋白质，多肽和多核苷酸序列; 和针对病毒上的抗原位点的抗体。这些组合物可用于各种用于FIV检测和接种疫苗的技术。所公开的检测方法包括病毒和病毒抗体的免疫测定，以及使用多核苷酸探针检测病毒基因组。疫苗包括全部和部分灭活的病毒灭活的表达FIV抗原的细胞系和亚单位疫苗。整个活的病毒也可用作预测人类免疫缺陷病毒（HIV）行为的示范系统。

4. 发明授权

US5665592A Feline immunodeficiency virus isolate NCSU.sub.1 失效
标题翻译：猫免疫缺陷病毒分离株NCSU1
公开(公告)号：US5665592A
公开(公告)日：1997-09-09
申请号：US365901
申请日：1994-12-29
申请人： Wayne A. F. Tompkins , Mary B. Tompkins
发明人： Wayne A. F. Tompkins , Mary B. Tompkins
IPC分类号： A01K67/027 , A61K39/00 , C07K14/155 , C12N7/00 , C12N5/00 , C12N7/02 , C12N15/49
CPC分类号： C07K14/005 , A01K67/027 , C12N7/00 , A61K39/00 , C12N2740/15021 , C12N2740/15022 , Y10S435/948
摘要： Disclosed is an isolated and purified feline immunodeficiency virus (FIV) culture having the identifying characteristics of FIV isolate NCSU.sub.1. A biologically pure culture of host cells containing a FIV having the identifying characteristics of FIV isolate NCSU.sub.1 is also disclosed, along with isolated and purified DNA coding for (a) an FIV having the identifying characteristics of FIV isolate NCSU.sub.1, or (b) an antigenic fragment of an FIV having the identifying characteristics of FIV isolate NCSU.sub.1. Various vaccine formulations containing active agents derived from the foregoing FIV virus, DNA encoding the virus, and DNA encoding antigenic fragments of the virus are also disclosed herein.Also disclosed are immunodeficient mice containing feline tissue, which feline tissue is capable of infection with a feline immunodeficiency virus such as (but not limited to) FIV isolate NCSU.sub.1.
摘要翻译：公开了具有FIV分离物NCSU1的鉴定特征的分离和纯化的猫免疫缺陷病毒（FIV）培养物。还公开了含有具有FIV分离物NCSU1的鉴定特征的FIV的宿主细胞的生物学纯培养物，以及分离和纯化的DNA，其编码（a）具有FIV分离物NCSU1的鉴定特征的FIV，或（b）抗原性具有FIV分离NCSU1的识别特征的FIV的片段。本文还公开了含有源自前述FIV病毒的活性剂，编码病毒的DNA和编码病毒的抗原性片段的DNA的各种疫苗制剂。还公开了含有猫组织的免疫缺陷小鼠，猫组织能够感染猫免疫缺陷病毒，例如（但不限于）FIV分离株NCSU1。

5. 发明授权

US5654195A Vectors expressing hybrid viruses, methods of use and novel assays 失效
标题翻译：表达杂合病毒的载体，使用方法和新的测定
公开(公告)号：US5654195A
公开(公告)日：1997-08-05
申请号：US268799
申请日：1994-07-01
申请人： Joseph Sodroski , William A. Haseltine , Norman Letvin , John Li
发明人： Joseph Sodroski , William A. Haseltine , Norman Letvin , John Li
IPC分类号： C12N15/09 , A01K67/027 , A61K39/00 , A61K39/21 , A61K49/00 , A61P31/12 , C07H21/04 , C07K14/155 , C07K14/16 , C12N7/00 , C12N15/49 , C12N15/867 , C12N15/86
CPC分类号： C12N15/86 , A01K67/027 , C07K14/005 , C12N7/00 , A61K39/00 , C12N2740/15021 , C12N2740/15043 , C12N2740/16021 , C12N2740/16043 , C12N2740/16122 , C12N2740/16222
摘要： A vector which can be used to establish a hybrid SIV/HIV-1 virus is described. This virus can be used to infect an animal such as a monkey to establish an animal model for in vivo testing. This animal model can be used for purposes such as screening for therapeutics, adjuvants and vaccines.
摘要翻译：描述了可用于建立混合型SIV / HIV-1病毒的载体。该病毒可用于感染动物如猴子以建立用于体内测试的动物模型。该动物模型可用于筛选治疗剂，佐剂和疫苗。

6. 发明授权

US5565319A Assay and apparatus for detecting feline immunodeficiency virus 失效
标题翻译：检测猫免疫缺陷病毒的方法和装置
公开(公告)号：US5565319A
公开(公告)日：1996-10-15
申请号：US226447
申请日：1994-04-12
申请人： Niels C. Pedersen , Janet K. Yamamoto
发明人： Niels C. Pedersen , Janet K. Yamamoto
IPC分类号： A61K39/00 , A61K39/21 , C07K14/155 , C12N7/00 , C12Q1/70 , G01N33/53 , G01N33/537 , G01N33/543
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , C12N7/00 , A61K2039/5252 , A61K2039/55516 , A61K2039/5555 , A61K39/00 , C12N2740/15021 , C12N2740/15022 , C12N2740/15034 , Y10S436/807
摘要： Compositions derived from a novel viral isolate designated feline T-lymphotropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).
摘要翻译：衍生自命名为猫T淋巴细胞慢病毒（FTLV）的新型病毒分离物的组合物包括全病毒; 蛋白质，多肽和衍生自病毒的多核苷酸序列; 和针对病毒上的抗原位点的抗体。这些组合物可用于检测和接种FTLV的各种技术。所公开的检测方法包括病毒和病毒抗体的免疫测定，以及使用多核苷酸探针检测病毒基因组。疫苗包括全部和部分灭活的病毒和亚单位疫苗。整个活的病毒也可用作预测人类免疫缺陷病毒（HIV）行为的示范系统。

7. 发明公开

US20230285591A1 NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE 审中-公开
公开(公告)号：US20230285591A1
公开(公告)日：2023-09-14
申请号：US18151174
申请日：2023-01-06
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Benhur LEE , Karina PALOMARES , Olivier PERNET
IPC分类号： A61K48/00 , A61K39/12 , C12N7/00 , C12N15/86
CPC分类号： A61K48/0008 , A61K39/12 , A61K48/00 , A61K48/0075 , C12N7/00 , C12N15/86 , C12N2740/15021 , C12N2740/15032 , C12N2740/15041 , C12N2740/15043 , C12N2740/15071 , C12N2760/18222 , C12N2760/18232 , C12N2760/18234 , C12N2760/18241 , C12N2760/18245 , C12N2760/18271 , C12N2810/6027 , C12N2810/6072
摘要： The present invention realtes to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glyocproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatetment of cancer or CNS disorders.

8. 发明申请

US20140193449A1 COMPOSITIONS AND METHODS FOR CANCER TREATMENT 审中-公开
标题翻译：用于癌症治疗的组合物和方法
公开(公告)号：US20140193449A1
公开(公告)日：2014-07-10
申请号：US14149911
申请日：2014-01-08
申请人： University Health Network
发明人： Jeffrey A. Medin , Andrea McCart , Severine Loisel-Meyer
IPC分类号： A61K39/21 , A61K39/00
CPC分类号： A61K39/0011 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2227/105 , A01K2267/0331 , A61K38/208 , A61K39/21 , A61K48/005 , A61K2039/5154 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , A61K2039/55522 , A61K2039/55538 , A61K2039/57 , A61K2039/575 , C07K14/5434 , C07K14/70503 , C07K2319/06 , C12N7/00 , C12N15/8509 , C12N15/86 , C12N2740/15021 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , C12N2740/16043
摘要： Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.
摘要翻译：公开了用于递送肿瘤相关抗原和免疫调节分子以产生治疗效果的组合物和方法。组合物和方法使用稳定整合的慢病毒递送系统。该方法可用于治疗和预防性治疗诸如结肠癌的癌症。

9. 发明申请

US20130143204A1 DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF 有权
标题翻译： VIVO DNA双重断裂定位及其应用的确定
公开(公告)号：US20130143204A1
公开(公告)日：2013-06-06
申请号：US13522225
申请日：2011-01-13
申请人： Christof Von Kalle , Manfred Schmidt , Richard Gabriel , Ali Nowrouzi , Anne Arens , Angelo Lombardo , Luigi Naldini
发明人： Christof Von Kalle , Manfred Schmidt , Richard Gabriel , Ali Nowrouzi , Anne Arens , Angelo Lombardo , Luigi Naldini
IPC分类号： C12Q1/68
CPC分类号： C12Q1/686 , C12N15/907 , C12N2740/15021 , C12N2740/15031 , C12N2740/15045 , C12Q1/6827 , C12Q1/6858 , C12Q1/70 , C12Q2521/301
摘要： The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease.
摘要翻译：本发明涉及用于确定宿主细胞中双链断裂的体内定位的方法，包括孵育疑似包含DNA双链断裂的宿主细胞和包含已知序列的线性多核苷酸，检测体内插入所述多核苷酸在所述宿主细胞的基因组中的位点，以及评估双链断裂的体内定位。本发明进一步设想的是获得具有改变的体内特异性的核酸内切酶的方法。最后，本发明涉及用于确定内切核酸酶的体内特异性的试剂盒。

10. 发明授权

US07026113B2 EIA vaccine and diagnostic 失效
公开(公告)号：US07026113B2
公开(公告)日：2006-04-11
申请号：US10180626
申请日：2002-06-26
申请人： Ronald Montelaro , Bridget Puffer , Feng Li , Charles Issel , Kristina J. Hennessy , Karen K. Brown
发明人： Ronald Montelaro , Bridget Puffer , Feng Li , Charles Issel , Kristina J. Hennessy , Karen K. Brown
IPC分类号： C12Q1/70 , C12Q1/68 , A61K48/00 , G01N33/53 , C12P19/34
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , C12N7/00 , C12N2740/15021 , C12N2740/15022 , C12N2740/15034 , C12N2740/15061 , Y10S424/82
摘要： The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式